ArticleGenes and immunity2025
Impact of tertiary lymphoid structure scores and their stage of maturation on prognosis of colorectal cancer patients.
Article in Genes and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical impact and therapeutic potential of tertiary lymphoid structures in melanoma.Frontiers in immunology · 2026Review
- Initiation of Tertiary Lymphoid Structures for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Review
- PLGA-based nanoparticles in colorectal cancer immunotherapy: current concepts and future perspectives.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLSs) are essential for promoting immune responses against tumours. However, the impact of TLS score and its maturation stage on the prognosis of colorectal cancer (CRC) patients has not yet been clarified. The aim of this study was to investigate the relationship between TLS score and its maturation stage and CRC prognosis through a retrospective study. In this study, firstly, high TLS score (≥0.752) was found to be a favourable prognostic factor for the survival of CRC patients using the TCGA database (HR = 0.381, 95% CI = 0.222 ~ 0.656). Secondly, CCL19, CCL21, and CXCL13 were found to be differential genes in the high and low TLS score groups in combination with several databases, and their main function was to chemotaxis TLS maturation. Subsequently, immunohistochemical staining was used to clarify the stage of TLS maturation in 76 clinical samples and to investigate its impact on patients' survival prognosis. Finally, the validation of TNFRSF17 gene function was completed by cellular experiments. Analysis of the clinical samples showed that patients with higher early TLS (E-TLS) density had shorter survival than those with lower density (P = 0.016). High E-TLS density may be an independent risk factor for CRC (HR = 6.40, 95% CI = 1.82 ~ 22.55). However, the density of secondary follicular-like TLS did not show a significant prognostic effect in this study. In conclusion, patients with high TLS scores had longer survival, higher expression of immune checkpoint genes, and higher expression of TNFRSF17, which promotes T-cell infiltration and adhesion, but highly aggregated E-TLS may hamper patients' survival prognosis.
Indexed as
Identifiers
40721500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.